Analysts project Zoetis to outpace consensus earnings estimates when it reports its quarterly results next week. The company’s animal health segment has delivered three consecutive quarters of double-digit revenue growth, driven by strong vaccine sales in North America and increased parasiticide demand in Europe. With operating margins expanding by 120 basis points over the past year and management forecasting free cash flow of approximately $1.4 billion for the full fiscal year, Zoetis appears to possess the key ingredients for an earnings beat and potential upward guide.

Zoetis carries a Zacks Momentum Style Score of 88, placing it in the top 12% of all stocks for price strength and relative performance. Over the past six months, shares have gained nearly 18%, outperforming the broader healthcare sector’s 10% rise. Institutional buying has increased in the last two quarters, with mutual funds and pension plans adding an estimated 5 million shares, signaling confidence from large investors in the company’s growth trajectory and R&D pipeline focused on companion animal therapeutics.

In the most recent trading session, Zoetis shares declined by 2.0%, a sharper drop than the 1.3% retreat seen in the S&P 500 Index. Trading volume jumped 35% above its 30-day average as profit-taking intensified following a seven-session rally. Despite the pullback, Zoetis maintains a strong balance sheet with net debt of approximately $3.2 billion and a cash position exceeding $1.1 billion, offering resilience against short-term volatility and supporting continued investment in global market expansion.